For research use only. Not for therapeutic Use.
GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies[1].
| Catalog Number | I027898 |
| CAS Number | 929492-71-7 |
| Synonyms | (3,5-dimethoxyphenyl)-[4-(2-methylphenyl)piperazin-1-yl]methanone |
| Molecular Formula | C20H24N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H24N2O3/c1-15-6-4-5-7-19(15)21-8-10-22(11-9-21)20(23)16-12-17(24-2)14-18(13-16)25-3/h4-7,12-14H,8-11H2,1-3H3 |
| InChIKey | YOXCWYCROVRVBS-UHFFFAOYSA-N |
| SMILES | CC1=CC=CC=C1N2CCN(CC2)C(=O)C3=CC(=CC(=C3)OC)OC |
| Reference | [1]. Karaboga H, et al. Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity. ACS Chem Biol. 2020 Nov 20;15(11):2916-2928. |
